Studying genetic and biological factors to assess personal cancer risk and recurrence
Looks for early signs of cancer risk or return in adults.
Plain-language title generated from the registry record
Registry title: A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
Key facts
- Where
- Candiolo, ItalySee the site
Where in Italy
- Fondazione del Piemonte per l'Oncologia IRCCS CandioloCandiolo, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione del Piemonte per l'Oncologia
- Trial code
- NCT07469709
- Record updated
- 13 March 2026
- Original description
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.Read full original descriptionShow less
A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.
The PRO-ACTIVE study includes the following activities:
* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction
Inclusion: Age >18 years; Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer; Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion; Patients with ovarian carcinomas; Patients with metastatic melanoma; Patients with stage IIB and IIIA non-small cell lung cancer.
Exclusion: Age <18 years; Unwillingness or inability to give informed consent.